Nasdaq rxrx.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …Published: Nov 02, 2023. SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16, 2023.4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.13 Tem 2023 ... The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation;” and so on. But rather more ...SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...

Jul 6, 2023 · Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares. 7 Eyl 2023 ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.

3 min read. ·. Jun 7, 2022. 2. Today we’re announcing the raise of two new Obvious funds, which combine to $461M of new capital: 4 We’ve completed the fundraise for our fourth flagship early ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES.

Netflix Inc (NASDAQ:NFLX): Bought 2,490 shares of the movie streaming company, representing about 0.199% of the ETF. Netflix stock closed 1.45% higher at $554.44 on Monday. It has a 52-week high ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. 31 Eki 2023 ... Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX).22 Kas 2023 ... That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands ...It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...

About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX). Though it still hasn't brought a product to market just ...For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Recursion Pharmaceuticals (NASDAQ:RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ:NVDA) in July rocketed its shares.Jul 12, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...

Pre-Market Quotes Nasdaq-100 Ownership Search News + Insights Solutions Recursion Pharmaceuticals, Inc. Class A Common Stock P/E & PEG Ratios …According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of …Dec 4, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it ...12 Eyl 2023 ... The average price target on the stock suggests an 88% gain from recent prices. Expand. NASDAQ: RXRX. Recursion ...

This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $9.00. The …Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Recursion Pharmaceuticals,...

According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.12 Eyl 2023 ... The average price target on the stock suggests an 88% gain from recent prices. Expand. NASDAQ: RXRX. Recursion ...SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Nov 26, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (0.43%) $0.03. Current Price. $7.05. ... (RXRX 0.43%) that aims to use artificial intelligence (AI) and petabytes of data as ... 16 Nis 2021 ... Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) rings the Nasdaq Stock Market Opening Bell remotely from Salt Lake City, Utah.Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $9.00. The …22 Kas 2023 ... That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands ...

RXRX Recursion Pharmaceuticals Inc Current Report Filing (8-k) The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of ...

Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...

20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...DocuSign (NASDAQ: DOCU) ... SDGR), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Amongst these choices, I would favor AbCellera Biologics in the current environment, ...SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX). Though it still hasn't brought a product to market just ...According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Founded in 2013, Recursion Pharmaceuticals is a Utah-based clinical stage "digital biotech", possessing a sophisticated robotized biology experimentation drug discovery platform, utilizing machine learning technologies, including high-throughput imaging analytics and high content …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Nov 24, 2023 · The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors? Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer.SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...Instagram:https://instagram. gold dividend stocks2u inc stockbest online mobile bankingwhat is rsi in stock RXRX Is Still Unprofitable. As a clinical stage biotech company, Recursion's financials are somewhat predictably steeped in red ink. The company has yet to report a profit - and even at that, its ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. fast growing stocks right nowtransfer ira to gold and silver Jan 12, 2022 · So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ... That's what's happening with Recursion Pharmaceuticals ( RXRX 1.18%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... dental plans virginia Based on analysts offering 12 month price targets for RXRX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Microsoft Corporation Common Stock. $376.39 +0.22 +0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...